Why the study?
How should ischaemic heart disease be managed in women of child-bearing age, particularly during pregnancy?
How should ischaemic heart disease be managed in women of child-bearing age, particularly during pregnancy?
Managing ischaemic heart disease in pregnant women is challenging due to limited safety data for standard diagnostic tests and treatments like ACE inhibitors, beta-blockers, and newer antiplatelet agents.
Case reports on CAD in pregnancy remain hypothesis-generating; prospective studies needed before guiding management.
Ischaemic heart disease is rare in young women but is expected to increase with increasing average age of child bearing. Diagnosis of myocardial ischaemia in this group is complicated by limited data about maternal and fetal safety of the standard diagnostic tests routinely used in other patients. Management of these patients remains difficult, as many standard treatments, such as beta-blockers and angiotensin converting enzyme inhibitors are pregnancy category C or D, and there is little experience with many of the newer treatments such as coronary artery stenting, clopidogrel and glycoprotein IIb/IIIa inhibitors in pregnancy. An interesting case of a woman, who had an acute myocardial infarction treated with thrombolysis and coronary artery stenting, and who subsequently became pregnant, is reported here, and other published reports regarding the management of coronary artery disease, both acute and chronic, in pregnant women are explored. (Intern Med J 2004; 34: 694−697)
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: